zepbound is glp 1 Oksana Aron, M.D., Medical Weight Loss, New York The Health Risks and Benefits

One understanding of your full health picture

Clinical trials and meta-analyses consistently show that DPP-4 inhibitors produce a modest but clinically meaningful reduction in HbA1c , typically in the range of: 0.5% to 1.0% (approximately 5.5 to 11 mmol/mol) when used as monotherapy or add-on therapy Reductions at the higher end of this range are more likely when baseline HbA1c is significantly elevated For example, sitagliptin has demonstrated reductions of around 0.60.8% in randomised controlled trials, while vildagliptin and saxagliptin show broadly comparable efficacy

We ensure that you receive personalized care and support throughout your journey to better health

PMID 22554099

RCT, Randomized Controlled Trial